Fresenius Medical Care AG (FMS) Form 6-K — Sep 25, 2026
Fresenius Medical Care announced a refinement of its China commercial strategy, focusing on a localized portfolio, locally relevant innovation, and a focused go-to-market approach in a market representing roughly 6-7% of Care Enablement segment revenues. The company will discontinue production and sales of the 4008A hemodialysis system in China and exit its China peritoneal dialysis business, while doubling down on advanced in-center dialysis technologies like the 5008S CAREsystem and multiFiltratePRO under new China General Manager Rex Liu.
Key figures
- Charge quarter
- Q3 2026
- Dialysis clinics
- 3513
- One time costs eur
- approximately €110 million
- Patients worldwide
- approximately 4.5 million
- Dialysis patients in clinics
- approx. 290,000
- China share of care enablement revenue
- 6-7%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.